about
Sociodemographic and lifestyle statistics of oldest old people (>80 years) living in ikaria island: the ikaria study.Consumption of a boiled Greek type of coffee is associated with improved endothelial function: the Ikaria study.Flavonoids in atherosclerosis: an overview of their mechanisms of action.Intracoronary thermography: does it help us in clinical decision making?Shear stress, protein kinases and atherosclerosis.Role of depression in heart failure--choosing the right antidepressive treatment.Low total testosterone levels are associated with the metabolic syndrome in elderly men: the role of body weight, lipids, insulin resistance, and inflammation; the Ikaria studyEndothelial dysfunction: potential clinical implications.Common community infections and the risk for coronary artery disease and acute myocardial infarction: evidence for chronic over-expression of tumor necrosis factor alpha and vascular cells adhesion molecule-1.From atherosclerosis to acute coronary syndromes: the role of soluble CD40 ligand.Inflammation in hypertension: current therapeutic approaches.Inflammatory markers in hyperlipidemia: from experimental models to clinical practice.Predictive value of biomarkers in patients with heart failure.Biomarkers determining cardiovascular risk in patients with kidney disease.Inflammatory mechanisms in atherosclerosis: the impact of matrix metalloproteinases.The role of matrix metalloproteinases in essential hypertension.Matrix metallopropteinases in heart failure.Heart rate as a therapeutic target in angina pectoris.Insight to the pathophysiology of stable angina pectoris.Targeting myocardial metabolism for the treatment of stable angina.Stable angina pectoris: current medical treatment.Novel risk factors related to stable angina.MicroRNAs: Novel diagnostic and prognostic biomarkers in atherosclerosis.Novel biomarkers assessing endothelial dysfunction: role of microRNAs.MicroRNAs: Biomarkers for cardiovascular disease in patients with diabetes mellitus.Prognostic role of miRNAs in coronary artery disease.MicroRNAs in aortic disease.The emerging role of microRNA in stroke.MicroRNAs in the diagnosis and treatment of unstable angina.MicroRNAs in cardiovascular therapeutics.Diabetes mellitus-associated vascular impairment: novel circulating biomarkers and therapeutic approaches.Statins in heart failure--With preserved and reduced ejection fraction. An update.Endothelial dysfunction in conduit arteries and in microcirculation. Novel therapeutic approaches.Smoking and atherosclerosis: mechanisms of disease and new therapeutic approaches.Effects of atorvastatin and vitamin C on forearm hyperaemic blood flow, asymmentrical dimethylarginine levels and the inflammatory process in patients with type 2 diabetes mellitus.Omega-3 PUFAs improved endothelial function and arterial stiffness with a parallel antiinflammatory effect in adults with metabolic syndrome.Vitamin D serum levels are associated with cardiovascular outcome in coronary artery disease.Serum osteoprotegerin and osteopontin levels are associated with arterial stiffness and the presence and severity of coronary artery disease.Mechanisms affecting platelet response to antiplatelet therapy in patients with ST-segment elevation myocardial infarction.Favorable effects of concord grape juice on endothelial function and arterial stiffness in healthy smokers.
P50
Q34170766-436F93D4-AB59-4712-9355-D5839A8D80ECQ34333898-853FDFC8-2D44-4790-BEEC-EEFD1F80C4C5Q34341836-4EDCF746-C685-4F7D-AA49-466AC0AE795AQ36335188-9F44DAF0-20E0-4275-AD30-A588A9BBE064Q36855468-AA020AD1-2012-4E3E-808F-AFE9B1BFE237Q37510208-C0A08237-220E-48CF-B65D-8BE75AFB3009Q37598204-05ADD554-36FE-4460-9B10-4D264F05394EQ37804682-27AC78A4-FE46-4E02-8FD1-D0F91F06417CQ37858546-165366CC-821B-46CC-B3D2-CF3056BE1CB6Q37899569-B2B199B4-74DE-4DA2-B1E8-37803ABF044EQ37971963-0F32485D-26FE-42A0-8732-3E9CCCB8E1EBQ37971965-E7F944D0-1BCA-43EB-93BD-64FDD6B9CF2DQ38001461-0F2F21E8-95D3-477D-B849-CE6D9E817842Q38001464-8E6068F3-2539-4EB8-9B76-B3907324238DQ38004039-E1C459A0-2243-484D-B8DC-B5D3D7FF655FQ38004040-DC201E26-B5D7-4B3F-9F12-F1A7EADDFF4AQ38004043-A13ECFD4-525B-464A-BFA1-5EE3C9AE5DE6Q38046955-42EA43BC-7E52-4BDE-ADBE-0E830D347402Q38046957-78AD681D-3F72-4376-8C97-9387C399E2DDQ38046958-F4294D46-D344-4541-AD53-17AADA170B93Q38046959-9084D7D2-BC81-4DB4-AAE8-42E84F628A63Q38046960-43F368EB-AF1D-4A9B-917B-4B5BCD702BD8Q38112763-84BE1B3E-4ACD-47AA-9CCE-D1B0EF0D7AC2Q38112765-D8060599-6D94-4E74-97B8-117151D8A2AAQ38112767-04D0116D-9707-4FB2-91D6-C7FE8D477C42Q38112768-04572F8D-2062-4C24-B2E3-21717E99B0A7Q38112770-2A0A4966-7503-40B3-BA6E-F0A472A5DC0CQ38112771-0156108B-8792-47FC-81FC-8A3CB769860AQ38112773-772D2A21-09B9-4D82-847E-1474BCE0AE04Q38112774-94098928-81CD-44DE-A6B7-B3AFC46C5393Q38129175-B0E7E026-94BB-41FD-AD97-E487C217302AQ38136062-14AC1D80-5FAF-4CD3-846E-2C26378350B3Q38220131-8D840182-837C-4EEB-8B51-B6A2D7796B9CQ38245015-175D4F69-0462-40F4-9096-58A97AFFCC6BQ42829070-9AC7D7B6-005A-4D67-9FD4-5B6243993E42Q43855545-24DAAC35-6C03-424C-B54D-7885E12DF2C6Q44233571-D43E24F4-F70B-474A-9161-A43D92756951Q44395349-A3C3FAE7-DA1E-4E5B-AF3D-26D395FAF6A3Q44471131-163531CF-E1F9-4E28-80F7-3FBCCB193697Q44500544-81087FD2-264B-49F4-B2C7-C024F5D3304E
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Gerasimos Siasos
@ast
Gerasimos Siasos
@en
Gerasimos Siasos
@es
Gerasimos Siasos
@nl
Gerasimos Siasos
@sl
type
label
Gerasimos Siasos
@ast
Gerasimos Siasos
@en
Gerasimos Siasos
@es
Gerasimos Siasos
@nl
Gerasimos Siasos
@sl
prefLabel
Gerasimos Siasos
@ast
Gerasimos Siasos
@en
Gerasimos Siasos
@es
Gerasimos Siasos
@nl
Gerasimos Siasos
@sl
P106
P1153
9732403100
P31
P496
0000-0003-0147-2862